Correction: Fry et al. Global Leadership for Sustainability. Sustainability 2021, 13, 6360

Fry, Louis W.; Egel, Eleftheria

doi:10.3390/su132112209

Cited by 3 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All five of the C-terminal domain kinases can phosphorylate Ser5, but only CDK9, CDK12, and CDK13 can phosphorylate at Ser2 [59,321,352]. Inhibitors R547 (pK i 9) [135], palbociclib (pIC 50 8) [183], Ro-0505124 (pIC 50 7.7) [144], riviciclib (pIC 50 7.2) [297], alvocidib (pK i 7.…”

Section: Cyclin-dependent Kinase (Cdk) Familymentioning

confidence: 99%

“…2) [79] palbociclib (pIC 50 7.8) [183] Comments on Cyclin-dependent kinase (CDK) family: The development of CDK inhibitors as anticancer drugs is reviewed in [576], with detailed content covering CDK4 and CDK6 inhibitors that are under clinical evaluation. Data produced by Jorda et al (2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes [296], as most of them are more promiscuous in their selectivity than indicated.…”

Section: Cdk4 Subfamilymentioning

confidence: 99%

See 1 more Smart Citation

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

Alexander

Fabbro

Kelly

et al. 2019

British J Pharmacology

477

431

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (http://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14752. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Cyclin-dependent Kinase (Cdk) Familymentioning

confidence: 99%

Section: Cdk4 Subfamilymentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

Alexander

Fabbro

Kelly

et al. 2019

British J Pharmacology

477

431

View full text Add to dashboard Cite

show abstract

“…The clinically used drugs temsirolimus and everolimus inhibit mTOR kinase activity. Inhibitors R547 (pK i 9) [149], palbociclib (pIC 50 8) [211], Ro-0505124 (pIC 50 7.7) [160], riviciclib (pIC 50 7.2) [342], alvocidib (pK i 7.…”

Section: Overviewmentioning

confidence: 99%

“…2) [86] palbociclib (pIC 50 7.8) [211] Comments on Cyclin-dependent kinase (CDK) family: The development of CDK inhibitors as anticancer drugs is reviewed in [592], with detailed content covering CDK4 and CDK6 inhibitors that are under clinical evaluation. Data produced by Jorda et al ( 2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes [341], as most of them are more promiscuous in their selectivity than indicated.…”

Section: Nomenclaturementioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2023/24: Enzymes

Alexander,

Fabbro,

Kelly

et al. 2023

British J Pharmacology

170

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16176. In addition to this overview, in which are identified ‘Other protein targets’ which fall outside of the subsequent categorisation, there are six areas of focus: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Catalyzing Green Identity and Sustainable Advantage in Tourism and Hotel Businesses

Alsheref,

Khairy,

Alsetoohy

et al. 2024

Sustainability

View full text Add to dashboard Cite

Global environmental concerns necessitate a heightened focus on green practices by businesses to balance sustainability and profitability. Therefore, this study investigates the effects of green ambidexterity (GA), green organizational identity (GOI), and green internal marketing (GIM) on sustainable competitive advantage (SCA) in travel agencies and hotels. The PLS-SEM approach was used to test the proposed model of the study. In total, 317 valid responses were gathered from full-time middle- and upper-management personnel of travel agencies category A and five-star hotels operating in Egypt. The findings revealed that GA positively impacts GOI, GIM, and SCA. Also, GOI and GIM positively impact SCA. In addition, GOI and GIM mediate the relationship between GA and SCA. The study advanced dynamic capability theory by emphasizing the importance of internal processes in harnessing sustainability-oriented dynamic capabilities. The study recognized the relationship between SCA, GOI, GIM, and GA and provided insightful implications on how businesses might develop and use their sustainability-related strengths.

show abstract

Correction: Fry et al. Global Leadership for Sustainability. Sustainability 2021, 13, 6360

Abstract: The authors would like to make the following corrections to the published paper [...]

Cited by 3 publications

References 1 publication

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

The Concise Guide to PHARMACOLOGY 2023/24: Enzymes

Catalyzing Green Identity and Sustainable Advantage in Tourism and Hotel Businesses

Contact Info

Product

Resources

About